View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. News
  2. Company News
September 7, 2018

M&As this week: SOTIO, United Therapeutics, Pediapharm

SOTIO has completed the acquisition of Cytune Pharma for an undisclosed sum.

SOTIO has completed the acquisition of Cytune Pharma for an undisclosed sum.

All products being developed by the target company will be brought into the acquirer company’s pipeline, under the acquisition.

First-in-human clinical trials for Cytune’s lead pipeline molecule SO-C101 (RLI-15) are expected to start in early 2019. SO-C101 will be a complementary addition to SOTIO’s clinical programmes in ovarian and prostate cancer based on its autologous immunotherapy platform, DCVAC.

Based in the Czech Republic, SOTIO is a biotechnology firm that is part of the PPF Group, while Cytune is a French biotechnology company engaged in the research and development of novel immunotherapeutic agents.

United Therapeutics has completed the acquisition of SteadyMed by acquiring all outstanding ordinary shares of the latter.

The acquisition was announced in April 2018 and approved by the shareholders of SteadyMed in July 2018.

“United Therapeutics has completed the acquisition of SteadyMed by acquiring all outstanding ordinary shares of the latter.”

Based in the US, United Therapeutics is a biotechnology company that develops and commercialises medicines for unmet medical needs, while SteadyMed, also based in the US, is a developer of therapeutic drugs.

The acquisition will enable United Therapeutics to market its pulmonary arterial hypertension drug, Trevyent® in Europe.

Canadian specialist pharmaceutical company Pediapharm has signed definitive agreements to acquire two pharmaceutical companies, Medexus and Medac Pharma.

Pediapharm has signed a stock purchase agreement with Medexus to acquire all the outstanding shares of the latter. The company has also entered an agreement with German pharmaceutical company, medac Gesellschaft, to acquire 100% shares of the latter’s US business, Medac Pharma.

Based in Canada, Medexus is a specialist pharmaceutical company, while Medac Pharma, also a specialist pharmaceutical company, is based in the US.

The acquisitions will enable Pediapharm to combine its Canadian paediatric pharmaceutical business with that of Medexus and Medac Pharma.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. A weekly roundup of the latest news and analysis, sent every Friday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Pharmaceutical Technology